Celltrio Secures $15 Million to Accelerate Global Expansion of Cell Therapy Automation Platform
核心洞察
Celltrio (搜索), a Fremont-based life sciences company, raised $15 million in funding led by Premier Partners (搜索) to accelerate global commercialization of its RoboCell (搜索) automation platform.
The investment will scale manufacturing capabilities and expand commercial operations across North America, Europe, and Asia for the company's cell culturing and cell therapy (搜索) automation solutions.
RoboCell (搜索) is a flagship modular platform that fully automates sterile cell culturing and cell therapy (搜索) manufacturing processes for biopharma, regenerative medicine, and research laboratories.
Celltrio (搜索), a Fremont, California-based life sciences company specializing in advanced automation solutions for cell culturing and cell & gene therapy, announced the closing of a $15 million funding round led by Premier Partners (搜索). The investment represents a significant milestone for the company as it seeks to transform cell-based therapy manufacturing through next-generation automation technology.
Strategic Investment to Drive Global Expansion
The funding will primarily accelerate the global commercialization of RoboCell (搜索), Celltrio (搜索)'s flagship modular platform designed for fully automated, sterile cell culturing and cell therapy (搜索) manufacturing. Investment proceeds will be strategically allocated to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia, and fuel continued innovation of GMP-ready automation solutions.
"This investment marks a major milestone for Celltrio (搜索) and validates our mission to streamline, scale, and standardize cell manufacturing through automation," said Charlie Duncheon, CEO of Celltrio. "We are thrilled to partner with Premier Partners (搜索), who share our vision of transforming the future of cell-based therapies with next-generation automation solutions."
RoboCell Platform Technology
Celltrio (搜索)'s RoboCell (搜索) system represents a comprehensive automation solution that fully automates processes in sterile cell culturing and cell and gene therapy (搜索) applications. The platform is designed to integrate seamlessly into both R&D and GMP environments, delivering high-throughput, consistent results for biopharma, cell therapy (搜索), and regenerative medicine laboratories.
The scalable cell culture automation platforms manufactured by Celltrio (搜索) address critical needs in the rapidly growing cell and gene therapy (搜索) sector, where standardization and scalability remain significant challenges for commercial manufacturing.
Investor Confidence and Market Validation
Premier Partners (搜索), a leading investment firm specializing in growth equity and growth buyout investments with approximately $2.9 billion in managed assets, expressed strong confidence in Celltrio (搜索)'s market position and technology differentiation.
"We are highly impressed by Celltrio (搜索)'s customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation," said Jay Song, CEO of Premier Partners (搜索). "We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide."
The investment from Premier Partners (搜索), which focuses on rapidly growing sectors within the healthcare industry and targets middle-market opportunities globally, underscores the significant market opportunity in cell therapy (搜索) automation and manufacturing solutions.
Market Impact and Future Outlook
The funding positions Celltrio (搜索) to capitalize on the expanding cell and gene therapy (搜索) market, where automation solutions are increasingly critical for achieving the scale and consistency required for commercial success. The company's focus on GMP-ready automation solutions addresses a key bottleneck in the industry, where manual processes often limit scalability and introduce variability in cell therapy (搜索) manufacturing.
With the new capital, Celltrio (搜索) is positioned to expand its global footprint and continue developing innovative automation technologies that could significantly impact how cell-based therapies are manufactured and delivered to patients worldwide.